Next Generation Business

日本語 English

The four business development divisions are taking the lead in our shift to a customer-driven model as we create new businesses.

Is there something we need or lack in our pursuit of a better society or better lives?
Mitsui Chemicals proactively strives to create the next generation of businesses by exploring the borders and peripheries of our traditional fields. In numerous areas, we cooperate with many different industries such as solar power, wind power and other forms of energy generation, healthcare, agriculture and IoT solutions, as we seek to expand into new areas.

Business Vision

Next Generation Business Mission
In Next Generation Business, our mission is to create solutions businesses through open innovation at the boundaries and in the peripheral areas of the three targeted growth domains of Mobility, Health Care and Food & Packaging. Across every business sector, collaborative initiatives are being undertaken, including in the New Health Care Business Development Division, the New Mobility Business Development Division, the Next Generation Business Development Division, and the Robot Materials Business Development Division.
For its part, the Next Generation Business Development Division’s mission is to challenge new business models. Instead of focusing on the development of large-scale next-generation businesses, its aim is to start small and build on successes while keeping an eye on the big picture. The division first examines whether ECRIOS™—Creating New Possibilities in Flexible Displays ECRIOS™ is a varnish for colorless polyimide with outstanding chemical resistance and heat resistance to temperatures in excess of 260°C. The flexible display manufacturing process subjects resins to harsh chemicals and high-temperature environments. ECRIOS™ stands up to such harsh conditions. Experienced in working in cooperation with customers to clear such product performance hurdles, we are positioned to provide innovative solutions like the revolutionary ECRIOS™ in new markets. there are customers wanting to buy a given product or service. Then, rather than devising a standard five-year, ¥1 billion in annual sales business plan, the division considers what it can begin selling tomorrow and works forward from that point, creating a new business model based on selling the “knowledge” of the Mitsui Chemicals Group. All the projects currently under examination in the four fields of agriculture, IoT, energy, and medicine originated from contacts with venture companies, universities, and other external entities. New businesses often cannot take off without external collaboration building win-win relationships. The Next Generation Business Development Division’s Corporate Venture Capital (CVC) Group is promoting the expansion of new businesses through open innovation.

Strategic Product Lineups

New Health Care Business Development Division

In healthcare, we are creating the next generation of businesses and establishing related business models by developing new products, contributing to improved quality of life as we do so.

New area of dental materials

Physical mobility

New Mobility Business Development Division

We will utilize our comprehensive strength and facilitate company-wide marketing activity in automobiles, an important market.
In mobility, our most important segment, we are creating new businesses such as POLYMETAC, a molded product integrating metal and resin, as well as the next-generation LiB business.

Multi-material compatibility and combination

Commercialization of provision of solutions

  • Solution business (e.g. molds)
  • Battery materials
  • Hybrid materials joining different materials
Next-Generation Business Development Division

In a rapidly changing business environment, we are creating the next generation of big business in new market areas, as we pursue rapid growth in scale and profits and enhanced corporate value.

Energy Solution Business

Agri-Solution Business

  • Resource-saving crop cultivation system (iCAST™)

Medical Solution Business

  • Rapid diagnostic system for bacterial identification
  • Enzyme kit (Contamination-free DNA polymerase)
  • DNA extraction kit (Contamination-free)

IoT Solution Business

(Corporate Venturing)

Robot Materials Business Development Division

Robots are drawing attention as a possible solution to a limited labor force and an aging society.
We are creating a new business and developing a business model in robot materials, an area that promises continued market expansion.

Departments

New Health Care Business Development Division
New Mobility Business Development Division
Next-Generation Business Development Division
  • Medical Solution Business
  • IoT Solution Business
Robot Materials Business Development Division

TOPICS - Special Feature on Strategic Products

Agricultural Systems Solutions

The iCAST™ Plant Cultivation System

iCAST™ originated with an idea conceived by an employee who had been given a blank canvas and encouraged by his manager to come up with new agriculture-related concepts.
What can Mitsui Chemicals do globally to give back to society?
Reflecting a market-oriented approach to helping solve food and water shortages, the basic idea behind iCAST™ was to create a new plant cultivation system that would conserve water while improving crop yield in food-producing areas facing water shortages.
This system ensures that plants receive the necessary elements for growth (water, nutrients and air) in only the necessary amounts as required. The system uses the absolute minimum amounts of water and fertilizer needed to grow healthy plants. iCAST™ is undergoing medium-scale testing in Japan as well as on farms in America and Australia that are facing severe water shortages.

An Integrated Plant Cultivation System
Liquid nutrients in a storage tank are sent through plant cultivation tubes to iCALM™ plant cultivation materials. Plants absorb the nutrients necessary for healthy growth from iCALM™ in appropriate amounts as needed.
IoT Solutions

ECRIOS™—Creating New Possibilities in Flexible Displays

ECRIOS™ is a varnish for colorless polyimide with outstanding chemical resistance and heat resistance to temperatures in excess of 260°C. The flexible display manufacturing process subjects resins to harsh chemicals and high-temperature environments.
ECRIOS™ stands up to such harsh conditions. Experienced in working in cooperation with customers to clear such product performance hurdles, we are positioned to provide innovative solutions like the revolutionary ECRIOS™ in new markets.

A precursor of the colorless polyamide ECRIOS™
Energy Solutions

An employee with over 10 years of experience in encapsulants saw some solar panels as he was going down the street one day and found himself questioning whether they really could last for 20 years.
One of subsidiary Mitsui Chemicals Tohcello, Inc.’s greatest strengths is its ability to predict the product service lives of panels thanks to its degradation prediction technology for the solar panel encapsulants that it has manufactured and sold for more than 25 years. Moreover, the subsidiary is now able to draw on its experience developing and operating the Tahara Solar-Wind™ solar power generation facility, a joint venture, to more accurately predict the volume of electricity generated. Specifically, it uses data accumulated at the Mobara Branch Factory and the prototype power plant at the Sodegaura Center while sharing power generation data with power plants nationwide in cooperation with investment funds.
By reporting on our findings, we aim to contribute to a healthy solar power market. Next, we have set our sights on Asia, and then the world. We are therefore taking a flexible approach to discovering needs for various services.

Medical Solutions

Rapid Identification System for Sepsis-Causing Bacteria

“Can plants cells be cultivated to produce the enzymes necessary to perform genetic testing?” This project began with this inquiry from Toyama University to our subsidiary Hokkaido Mitsui Chemicals, Inc. (HMCI).
Sepsis is a bacterial infection with a high mortality rate. Antibacterial drugs will kill the bacteria causing the infection, but because it takes 2-3 days to identify the particular strain, the current treatment is to use full-spectrum antibacterial drugs. There is the risk that such drugs will be ineffective or the bacteria will develop drug resistance. Sepsis is a disease where mortality rates increase by the hour, so being able to quickly identify the causal bacteria is key.
Using a basic system already developed by Toyama University, it is already possible to increase the volume of bacterial DNA in a patient’s blood sample to the level needed for testing, but false positives are a problem due to the foreign bacterial contamination of commercially sold enzymes that play a key role in identifying the bacteria. HMCI, which has researched and developed plant cells for more than 30 years, had the idea to devise a production process using yeast. In 2012, Mitsui Chemicals began research to commercialize this idea.

TOPICS - Helping to Address Social Issues

Helping to Save Lives by Contributing to the Development of a World-First Groundbreaking System

With Toyama University, the Mitsui Chemicals Group has jointly developed a world-first groundbreaking system that is able to identify the bacteria causing sepsis within about five hours. Previously, blood culture techniques that required large blood samples were used. The development of genetic testing methods that can use smaller blood samples has made it possible to more easily diagnose infants and small children. This joint development was undertaken through an innovative setup scheme under the Industrial-Academic Collaboration Medical Innovation Promotion Program at the Japan Agency for Medical Research and Development.
At the 28th Japan Clinical Microbiology Conference and Technical Exhibition, this system was reported to have saved the lives of several infants and children. Helping to create a system that saves lives benefits both society and the Group. Although market development has only just begun, we aim to clear each hurdle and bring more diagnostic agents to market.